Turn.bio has announced that its proprietary cellular reprogramming technology was able to significantly increase the proliferative and cytotoxic potential of premanufactured CAR-T cells in vitro. Turn.bio, a developer of mRNA-based cellular reprogramming technologies, has announced … Continue reading Turn.bio Announces Preliminary Results of a CAR-T Cell Study